Stock EIGR EIGER BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eiger BioPharmaceuticals, Inc.

Equities

EIGR

US28249U2042

Market Closed - OTC Markets
Other stock markets
 03:54:54 2024-06-03 pm EDT 		5-day change 1st Jan Change
2.3 USD 0.00% Intraday chart for Eiger BioPharmaceuticals, Inc. +9.52% -65.85%
May. 08 Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million. CI
May. 06 Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug
Eiger Biopharmaceuticals, Inc. Appoints Douglas Staut to Serve as the Company's Chief Restructuring Officer
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Motion for Joint Administration Approved for Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors
Sector Update: Health Care Stocks Slide Late Afternoon
Top Midday Decliners
Sector Update: Health Care
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection; Shares Fall
Motion for Joint Administration Filed by Eiger BioPharmaceuticals, Inc.
Eiger BioPharmaceuticals, Inc. Filed for Bankruptcy
Eiger BioPharmaceuticals, Inc. Announces Christine A. Murray Notifies Resignation as Member of Board of Directors, Effective March 15, 2024
Ldon Mayer Iii Notifies Eiger BioPharmaceuticals, Inc. of His Resignation as the Chief Commercial Officer, Effective February 2, 2024
Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
Moshe Arkin Sends a Letter to Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eiger to discontinue hepatitis drug study over safety concerns
Eiger to discontinue hepatitis drug study
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EIGR Stock
  4. News Eiger BioPharmaceuticals, Inc.
  5. Other languages